The Allogene Therapeutics Fourth Quarter 2025 Conference Call
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment…
TD Cowen 46th Annual Health Care Conference
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.…
Citi’s 2026 Virtual Oncology Leadership Summit
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Piper Sandler 36th Annual Healthcare Conference
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
The Citizens JMP Hematology and Oncology Summit
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
Jefferies London Healthcare Conference
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.